Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare CNSX:ATT NYSEARCA:IPO CVE:JTC On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATTAbattis BioceuticalsC$0.00C$0.05▼C$0.74N/AN/A1.42 million shsN/AIPORenaissance IPO ETF$49.36-2.0%$45.06$39.31▼$54.68$143.14M1.3227,574 shs20,292 shsJTCJEMTECC$1.10C$1.25C$0.71▼C$1.60C$3.08M0.2277743,013 shs110 shs7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATTAbattis Bioceuticals0.00%0.00%0.00%0.00%0.00%IPORenaissance IPO ETF0.00%+3.92%+14.87%+13.86%+24.62%JTCJEMTEC0.00%-6.78%+8.91%-29.49%+22.22%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATTAbattis BioceuticalsC$0.00C$0.05▼C$0.74N/AN/A1.42 million shsN/AIPORenaissance IPO ETF$49.36-2.0%$45.06$39.31▼$54.68$143.14M1.3227,574 shs20,292 shsJTCJEMTECC$1.10C$1.25C$0.71▼C$1.60C$3.08M0.2277743,013 shs110 shs7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATTAbattis Bioceuticals0.00%0.00%0.00%0.00%0.00%IPORenaissance IPO ETF0.00%+3.92%+14.87%+13.86%+24.62%JTCJEMTEC0.00%-6.78%+8.91%-29.49%+22.22%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceATTAbattis Bioceuticals 0.00N/AN/AN/AIPORenaissance IPO ETF 2.60Moderate Buy$49.36N/AJTCJEMTEC 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookATTAbattis BioceuticalsN/AN/AN/AN/AN/AN/AIPORenaissance IPO ETFN/AN/AN/AN/AN/AN/AJTCJEMTECC$1.90M1.62C$0.61 per share1.80C$0.84 per share1.31Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateATTAbattis BioceuticalsN/AN/AN/AN/AN/AN/AN/AN/AN/AIPORenaissance IPO ETFN/AN/A35.63N/AN/AN/AN/AN/AN/AJTCJEMTECN/AC$0.0715.71N/AN/A2.74%1.87%2.06%N/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthATTAbattis BioceuticalsN/AN/AN/AN/AN/AIPORenaissance IPO ETF$0.260.53%N/AN/AN/AJTCJEMTECN/A7.14%N/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioATTAbattis BioceuticalsN/AN/AN/AIPORenaissance IPO ETFN/AN/AN/AJTCJEMTEC0.4011.9514.45Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipATTAbattis BioceuticalsN/AIPORenaissance IPO ETFN/AJTCJEMTEC18.25%Insider OwnershipCompanyInsider OwnershipATTAbattis BioceuticalsN/AIPORenaissance IPO ETFN/AJTCJEMTEC50.14%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableATTAbattis BioceuticalsN/AN/AN/ANot OptionableIPORenaissance IPO ETFN/A2.90 millionN/ANot OptionableJTCJEMTECN/A2.80 millionN/ANot OptionableIPO, ATT, JTC, and AJB HeadlinesRecent News About These CompaniesJEMTEC Boosts Q1 Profit on Revenue Growth and Lower Direct CostsDecember 18, 2025 | tipranks.comJEMTEC Inc. Announces Special Dividend Amid Strong Financial OutlookApril 3, 2025 | tipranks.comJEMTEC 2023 Q1 & FINANCIAL UPDATEDecember 14, 2022 | technews.tmcnet.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesThe Real SpaceX Play: 5 Chip Stocks Powering the IPO Before It LaunchesBy Bridget Bennett | May 4, 20265 Space Stocks Already Climbing Ahead of the SpaceX IPOBy Bridget Bennett | April 14, 2026Could These 3 New-to-Market Quantum Computing Firms Threaten D-Wave?By Nathan Reiff | April 19, 2026PepsiCo Stock Reversal Points Toward New All-Time HighsBy Thomas Hughes | April 16, 2026SpaceX IPO Frenzy: 3 Space Stocks That Could Benefit MostBy Chris Markoch | April 20, 2026IPO, ATT, JTC, and AJB Company DescriptionsAbattis Bioceuticals CNSX:ATTAbattis Bioceuticals Corp. is a specialty biotechnology company. The Company aggregates, incubates, integrates and invests in the natural health product and botanical drug development industry. It operates through the segment of producing, licensing and marketing ingredients and formulas for use in the biopharma, nutraceutical, cosmetic and animal nutrition markets. The Company, through its subsidiaries, develops and commercializes natural health (nutraceutical) products, and conducts research and development to create plant-based (botanical) intellectual property and ingredients for the pharmaceutical and bioceutical markets, among others. It offers products and services, such as botanical blends and formulas; cannabidiol ingredients; functional foods and beverages, and analytical services. It is focused on creating botanical formulations, medical marijuana and specialized health products for pain caused by inflammation, and mental ailments.Renaissance IPO ETF NYSEARCA:IPO$49.36 -1.01 (-2.01%) As of 05/8/2026 04:10 PM EasternThe Renaissance IPO ETF (IPO) is an exchange-traded fund that is based on the FTSE Renaissance IPO index. The fund tracks a market cap-weighted index of recent US-listed IPOs. The fund acquires issues within 90 days or sooner after IPO and sells after 3 years. IPO was launched on Oct 14, 2013 and is managed by Renaissance.JEMTEC CVE:JTCC$1.10 0.00 (0.00%) As of 05/5/2026 12:58 PM EasternJEMTEC Inc. provides integrated technology systems for community-based corrections in Canada. It offers services and technologies for offender monitoring in Canadian federal and provincial correctional departments. The company also provides various levels of technology, which allows corrections, courts, and police to select from various options ensuring the correct level of offender control. n addition, its offender location detection/verification technologies include offender reporting through telephone contact, offender reporting kiosks with integrated database, global positioning system active and passive tracking, voice verification, electronic monitoring house arrest systems, remote alcohol in-home monitoring, and private monitoring services. JEMTEC Inc. was incorporated in 1981 and is headquartered in North Vancouver, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/04 - 05/08 SoundHound’s Bottom Is In—Inflection and 50% Upside Ahead? Rocket Lab Posts Record Q1 Revenue, Raises Q2 Guidance Hims & Hers Earnings Preview: The Novo Nordisk Shift Puts GLP-1 Strategy in Focus AppLovin Pops After Earnings With Growth Catalysts in Sight Dutch Bros Q1 Earnings: The Newest Starbucks Rival Faces Its First Big Reality Check The AI Fear Around Datadog Stock May Have Been Completely Wrong Amprius Technologies Ups the Voltage on Forward Outlook Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.